N.H. lawmakers advance proposal to eliminate hepatitis B vaccine requirement

New Hampshire’s House passed House Bill 1719 by a 186-168 vote to remove hepatitis B from the state list of school-required vaccines, aligning with recent federal Advisory Committee on Immunization Practices guidance that moved away from a universal newborn dose. The bill, backed by GOP sponsor Rep. Kelley Potenza and opposed by public health experts and medical societies that cite a 99% decline in cases since the 1991 universal recommendation, now goes to the House Finance Committee and would still require Senate approval and the governor’s signature, with advocates expecting resistance in those chambers.

Analysis

Market structure: This is a localized policy move with asymmetric winners/losers — downside concentrated in US pediatric hepatitis B vaccine demand (disproportionately impacts small-cap specialist Dynavax (DVAX) and, to a much smaller degree, pediatric vaccine SKUs at MRK/GSK). Impact to large diversified vaccine franchises is likely <2% revenue shock; combo-vaccine dynamics (Pediarix/Hexavalent) mute direct volume loss because providers may continue using combination products. Pricing power shifts are negligible at national pharma scale but concentrated market-share risk exists for single-indication suppliers.

Risk assessment: Immediate market reaction should be muted (days); short-term (3–12 months) tail risk is policy contagion — if 3+ US states advance similar bills within 12 months, anticipate a 10–30% demand erosion for standalone pediatric HepB in the US; long-term (1–3 years) downside grows if federal guidance permanently changes or maternal screening relaxes. Hidden dependency: combination vaccine take-rates and hospital birthing protocols (postpartum prophylaxis) are chokepoints that could preserve demand even if school mandates drop. Catalysts: state legislative advances, ACIP/federal reversals, and outbreak reports.

Trade implications: Prefer small, hedged directional exposure — size positions to 0.5–2% notional of portfolio. Direct short candidate: DVAX given single-product exposure; relative-value: long diversified vaccine winners (MRK, ticker MRK) vs short DVAX. Use options to cap risk (9–12 month put spreads on DVAX) rather than naked shorts. Avoid broad sector exits; rotate modestly into large-cap diversified vaccine/biotech names and healthcare services that benefit from increased testing/management costs.

Contrarian angle: Consensus overstates immediate revenue loss; historical precedent (1991 universal rollout) shows policy can re-reinstate mandates after outbreaks — risk of policy reversal creates asymmetric upside for a hedged long if contagion fails. Therefore prefer option-structured trades that monetize downside contagion while preserving upside optionality if mandates return within 12–24 months.

Key Decisions for Investors

• Establish a small short position in Dynavax (DVAX) sized 0.5–1.0% of portfolio notional over a 6–12 month horizon; place a stop-loss at +20% and target 20–35% downside if legislative contagion reaches ≥3 states within 12 months.
• Buy a 9–12 month DVAX put spread (size = 0.5% notional) to cap downside: buy long-dated put and sell a lower-strike put to fund cost (example structure: buy 12-month ITM put, sell 12-month 30–40% OTM put) — adjust strikes to current price at execution.
• Initiate a 1–2% long position in Merck (MRK) or GlaxoSmithKline (GSK) to hold diversified vaccine exposure; plan to add another 1% if no policy contagion in 6 months and pediatric vaccine volumes remain stable.
• Trigger-based rebalancing: monitor state-level bills and ACIP guidance for the next 30–90 days; if ≥3 states advance similar HB removal bills within 12 months, increase short DVAX exposure to 2–3% and buy additional 12-month puts; if none materialize and CDC/ACIP or state epidemiologists issue strong pro-vaccine guidance, cover shorts and consider small long DVAX swing trade (6–12 months).